Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium


Last updated date
Study Location
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-120 years


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral CancerSunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
  1. New York, New York
18 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Official Title  ICMJE Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium
Brief Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.

Detailed Description



  • Determine the response rate in patients with progressive metastatic transitional cell carcinoma of the urothelium treated with sunitinib malate.
  • Determine the safety of this regimen in these patients.


  • Determine the time to disease progression in patients treated with this regimen.

    • To determine time to tumor progression (TTP) for sunitinib malate on a continuous dosing schedule for treatment of metastatic urothelial carcinoma.
    • To estimate sunitinib and SU012662 trough plasma concentration (Ctrough) data for the continuous daily schedule and to determine potential association with efficacy and safety.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Bladder Cancer
  • Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Urethral Cancer
Intervention  ICMJE Drug: sunitinib malate
Study Arms  ICMJE Experimental: Sunitinib
This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
Intervention: Drug: sunitinib malate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 19, 2012)
Original Enrollment  ICMJE
 (submitted: November 8, 2006)
Actual Study Completion Date  ICMJE February 2012
Actual Primary Completion Date February 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  • Histologically confirmed transitional cell carcinoma of the urothelium, including 1 of the following sites:

    • Bladder
    • Urethra
    • Ureter
    • Renal pelvis
  • Progressive metastatic disease

    • Progressive disease defined as new or progressive lesions on cross-sectional imaging
    • Progressed despite prior treatment with cytotoxic chemotherapy
  • Measurable disease
  • Previously treated disease, as defined by the following:

    • Received treatment with 1-4 cytotoxic agents
    • Prior therapy must have included ? 1 of the following:

      • Cisplatin
      • Carboplatin
      • Paclitaxel
      • Docetaxel
      • Gemcitabine hydrochloride
    • Prior cytotoxic agents in the perioperative or metastatic setting allowed and may have been administered sequentially (e.g., first-line treatment followed by second-line treatment at time of progression) or all as part of a single regimen
  • No symptomatic CNS metastases


  • Karnofsky performance status 60-100%
  • Absolute neutrophil count ? 1,000/mm³
  • Platelet count ? 100,000/mm³
  • Hemoglobin ? 8.0 g/dL
  • Bilirubin ? 1.5 mg/dL (unless Gilbert's disease is present)
  • AST and ALT ? 2.5 times upper limit of normal (ULN) (5 times ULN if liver function abnormalities are due to underlying malignancy)
  • Creatinine ? 2.0 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Severe or unstable angina
    • Coronary or peripheral artery bypass graft
    • Symptomatic congestive heart failure
    • Cerebrovascular accident or transient ischemic attack
    • Pulmonary embolism
  • No ongoing cardiac dysrhythmias ? grade 2
  • No prolonged QTc interval on baseline ECG
  • No uncontrolled hypertension, defined as blood pressure > 150/100 mm Hg despite optimal medical therapy
  • No preexisting thyroid abnormality (i.e., thyroid function tests that cannot be maintained in the normal range with medication)
  • No known HIV- or AIDS-related illness or other active infection


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy or chemotherapy
  • At least 4 weeks since prior major surgery
  • No other concurrent investigational drugs
  • No concurrent participation in another clinical trial (supportive care trials or non-treatment trials [e.g., quality of life] allowed)
  • No concurrent therapeutic doses of warfarin (low-dose warfarin ? 2 mg once daily for thromboembolic prophylaxis allowed)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00397488
Other Study ID Numbers  ICMJE 06-081
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Memorial Sloan Kettering Cancer Center
Study Sponsor  ICMJE Memorial Sloan Kettering Cancer Center
Collaborators  ICMJE
  • National Cancer Institute (NCI)
  • Pfizer
Investigators  ICMJE
Principal Investigator:Dean F. Bajorin, MDMemorial Sloan Kettering Cancer Center
PRS Account Memorial Sloan Kettering Cancer Center
Verification Date December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP